Impact of Fluocinonide 0,05% in Oral Lichen Planus

• Status: Recruiting
• Trial end date: 2024-01-03
• Target enrollment: 0
• Participant gender: All

Summary

A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of Fluocinonide 0,05% and determinate the statistical significance of the outcome variables. Oral cavity lichen is a chronic inflammatory condition affecting the mucosa of the oral cavity , which significantly reduces the quality of life of affected individuals.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Catania
• Treatments: Fluocinonide

Criteria

Inclusion Criteria:

• Clinical and histologic diagnosis of Lichen Planus Orale;

• Presence of symptoms related to Lichen Planus Orale;

• Clinical follow-up period of at least 12 weeks;

• Acceptance of informed consent

Exclusion Criteria:

• State of pregnancy or lactation; h

• Histologic signs of dysplasia;

• Medications that induce a lichenoid response (ACE inhibitors, β-blockers, etc.);

• Presence of amalgam fillings in the vicinity of lesions;

• Treatment of oral lichen in the previous 6 months from the start of the program;

• Presence of extraoral lesions (genital, skin, etc.);

• Diabetes being treated with oral hypoglycemic drugs;

• History of previous immunodeficiency;

• HIV seropositivity;

• Previous allogeneic bone marrow transplantation;

• Diagnosis of LES or other autoimmune disease